Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Current Assets (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Current Assets for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 1947.01% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 1947.01% year-over-year, with the annual reading at $1.5 million for FY2025, 1947.01% up from the prior year.
  • Current Assets hit $1.5 million in Q4 2025 for Mangoceuticals, up from $598223.0 in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $3.8 million in Q1 2023 to a low of $75595.0 in Q4 2024.
  • Historically, Current Assets has averaged $1.0 million across 3 years, with a median of $557892.0 in 2024.
  • Biggest five-year swings in Current Assets: plummeted 97.65% in 2024 and later soared 1947.01% in 2025.
  • Year by year, Current Assets stood at $835402.0 in 2023, then crashed by 90.95% to $75595.0 in 2024, then skyrocketed by 1947.01% to $1.5 million in 2025.
  • Business Quant data shows Current Assets for MGRX at $1.5 million in Q4 2025, $598223.0 in Q3 2025, and $117961.0 in Q2 2025.